Related Experiment Video
Updated: Apr 21, 2026

07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.1K
Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma
Dequan Xu1, Xiaoying Lv1, Song Wang1
1Department of General Surgery, The First Affiliated Hospital of Harbin Medical University Harbin, China.
International Journal of Clinical and Experimental Pathology
|October 23, 2014
Summary
Predicting central compartment lymph node metastasis in papillary thyroid microcarcinoma (PTMC) is crucial. Key factors include male gender, larger tumor size, bilateral tumors, and capsule invasion, aiding treatment decisions.
Area of Science:
- Endocrinology
- Oncology
- Surgical Pathology
Background:
- Papillary thyroid microcarcinoma (PTMC) presents unique challenges in predicting lymph node metastasis.
- Accurate prediction of central compartment lymph node metastasis (CLNM) is vital for appropriate patient management.
Purpose of the Study:
- To identify predictive factors for CLNM in patients with PTMC.
- To aid in the decision-making process for prophylactic central compartment lymph node dissection (CLND).
Main Methods:
- Retrospective analysis of PTMC patients treated at a single institution.
- Statistical analysis of clinicopathological factors including age, sex, tumor size, multifocality, and capsular invasion.
Main Results:
- Tumor size greater than 5 mm, bilateral tumor presentation, and capsule invasion were independently predictive of CLNM.
- Tumor location in the lower third of the thyroid lobe was associated with increased CLNM risk in solitary tumors.
Conclusions:
- Preoperative and intraoperative identification of risk factors like male gender, tumor size > 5 mm, bilateral/multifocal disease, lower third location, and capsule invasion can guide CLND decisions.
- These findings support tailored prophylactic CLND strategies for PTMC patients.
Keywords:
Papillary thyroid carcinomacentral lymph nodelymph node dissectionlymph node metastasesthyroid microcarcinoma
